Indexed In
- Open J Gate
- Genamics JournalSeek
- China National Knowledge Infrastructure (CNKI)
- Ulrich's Periodicals Directory
- RefSeek
- Hamdard University
- EBSCO A-Z
- OCLC- WorldCat
- Publons
- Google Scholar
Useful Links
Share This Page
Journal Flyer
Open Access Journals
- Agri and Aquaculture
- Biochemistry
- Bioinformatics & Systems Biology
- Business & Management
- Chemistry
- Clinical Sciences
- Engineering
- Food & Nutrition
- General Science
- Genetics & Molecular Biology
- Immunology & Microbiology
- Medical Sciences
- Neuroscience & Psychology
- Nursing & Health Care
- Pharmaceutical Sciences
Value of pharmacometrics analyses in drug development
Joint Meeting on International Conference on Pharmacology and Toxicology & 18th International Conference on Medicinal and Pharmaceutical Chemistry
October 18-19, 2018 Dubai, UAE
Yuying Gao
Certara China, USA
Scientific Tracks Abstracts: Clin Exp Pharmacol
Abstract:
The process of drug development is extremely time consuming and costly. It takes approximately 10-12 years and costs hundreds of millions or billions dollars. Pharmacometrics is the scientific discipline that uses mathematical models based on biology, pharmacology, physiology, and disease for quantifying the interactions between drugs and patients. Its purpose is to reduce cost and shorten development time by optimizing the clinical assessment of efficacy and safety. This presentation highlights the value of pharmacometric analyses in drug development through selected examples.
Biography :
Yuying Gao is a trained anesthesiologist and clinical pharmacologist with more than 100 published books, manuscripts and abstracts and 20 years of modeling and simulation experience in optimizing treatment and bridging strategies, trial designs and drug development decision-making. In 2006, she joined Certara (formerly Quantitative Solutions) in its infancy and served as director of the Drug Development Consulting Services, general manager of Asia-Pacific region, and vice president, most recently as President and CEO of Certara Strategic Consulting China. Prior to joining us in 2006, she was senior scientist at the Pharsight Corporation (now Certara) from 1999 to 2006. During her career in both medical and consulting services, she has established herself as a thought expert in the field of anesthesiology and pharmacometrics. She has worked with more than 60 pharmaceutical companies and modeled more than 150 compounds in clinical development. Her work covers all therapeutic areas with recent focus on cardiovascular disease, oncology and neuroscience.
E-mail: yuying.gao@certara.com